Garoffolo Gloria, Pesce Maurizio
Unità di Ingegneria Tissutale Cardiovascolare, Centro Cardiologico Monzino, IRCCS, Milan, Italy.
Curr Res Pharmacol Drug Discov. 2021 May 25;2:100036. doi: 10.1016/j.crphar.2021.100036. eCollection 2021.
Cardiac fibrosis is characterized by extracellular matrix deposition in the cardiac interstitium, and this contributes to cardiac contractile dysfunction and progression of heart failure. The main players involved in this process are the cardiac fibroblasts, which, in the presence of pro-inflammatory/pro-fibrotic stimuli, undergo a complete transformation acquiring a more proliferative, a pro-inflammatory and a secretory phenotype. This review discusses the cellular effectors and molecular pathways implicated in the pathogenesis of cardiac fibrosis and suggests potential strategies to monitor the effects of specific drugs designed to slow down the progression of this disease by specifically targeting the fibroblasts.
心脏纤维化的特征是细胞外基质在心脏间质中沉积，这会导致心脏收缩功能障碍和心力衰竭的进展。参与这一过程的主要细胞是心脏成纤维细胞，在促炎/促纤维化刺激存在的情况下，它们会经历完全转变，获得更具增殖性、促炎和分泌性的表型。这篇综述讨论了与心脏纤维化发病机制相关的细胞效应器和分子途径，并提出了潜在的策略，以监测旨在通过特异性靶向成纤维细胞来减缓该疾病进展的特定药物的效果。
